Royalty Pharma Plc (RPRX) - Total Liabilities
Based on the latest financial reports, Royalty Pharma Plc (RPRX) has total liabilities worth $9.91 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Royalty Pharma Plc (RPRX) cash conversion ratio to assess how effectively this company generates cash.
Royalty Pharma Plc - Total Liabilities Trend (2000–2025)
This chart illustrates how Royalty Pharma Plc's total liabilities have evolved over time, based on quarterly financial data. Check Royalty Pharma Plc (RPRX) asset resilience to evaluate the company's liquid asset resilience ratio.
Royalty Pharma Plc Competitors by Total Liabilities
The table below lists competitors of Royalty Pharma Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Songfa Ceramics Co
SHG:603268
|
China | CN¥38.16 Billion |
|
Kuehne & Nagel
SW:KNIN
|
Switzerland | CHF9.73 Billion |
|
Chongqing Sokon Ind Grp Co
SHG:601127
|
China | CN¥92.78 Billion |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
USA | $9.55 Billion |
|
China Everbright Bank Co Ltd
SHG:601818
|
China | CN¥6.65 Trillion |
|
Wipro Limited
F:WIOA
|
Germany | €448.06 Billion |
|
Hapag Lloyd AG
XETRA:HLAG
|
Germany | €11.41 Billion |
|
Norsk Hydro ASA
OL:NHY
|
Norway | Nkr101.20 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Royalty Pharma Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RPRX market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Royalty Pharma Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Royalty Pharma Plc (2000–2025)
The table below shows the annual total liabilities of Royalty Pharma Plc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.91 Billion | +25.70% |
| 2024-12-31 | $7.88 Billion | +25.13% |
| 2023-12-31 | $6.30 Billion | -13.59% |
| 2022-12-31 | $7.29 Billion | +0.29% |
| 2021-12-31 | $7.27 Billion | +18.67% |
| 2020-12-31 | $6.12 Billion | -2.92% |
| 2019-12-31 | $6.31 Billion | -7.47% |
| 2018-12-31 | $6.82 Billion | -1.25% |
| 2017-12-31 | $6.90 Billion | +14.65% |
| 2016-12-31 | $6.02 Billion | -1.58% |
| 2015-12-31 | $6.12 Billion | +209153.76% |
| 2014-12-31 | $2.92 Million | -17.68% |
| 2013-12-31 | $3.55 Million | -6.48% |
| 2012-12-31 | $3.80 Million | +171.67% |
| 2011-12-31 | $1.40 Million | +7.70% |
| 2010-12-31 | $1.30 Million | -45.87% |
| 2009-12-31 | $2.40 Million | -65.69% |
| 2008-12-31 | $6.99 Million | +97.49% |
| 2007-12-31 | $3.54 Million | -12.81% |
| 2006-12-31 | $4.06 Million | +458.32% |
| 2005-12-31 | $727.00K | +18.40% |
| 2004-12-31 | $614.00K | +13.49% |
| 2003-12-31 | $541.00K | +4.24% |
| 2002-12-31 | $519.00K | -91.82% |
| 2001-12-31 | $6.34 Million | -31.88% |
| 2000-12-31 | $9.31 Million | -- |
About Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabe… Read more